These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1401 related items for PubMed ID: 14664658

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.
    Wilde MI, Goa KL.
    Drugs; 1996 May; 51(5):865-94. PubMed ID: 8861551
    [Abstract] [Full Text] [Related]

  • 23. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.
    Hesse UJ, Troisi R, Jacobs B, Van Vlem B, de Hemptinne B, Van Holder R, Vermassen F, De Roose J, Lameire N.
    Clin Transplant; 2000 Aug; 14(4 Pt 1):340-4. PubMed ID: 10945205
    [Abstract] [Full Text] [Related]

  • 24. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.
    Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C.
    Cochrane Database Syst Rev; 2014 Jun 05; 2014(6):CD010253. PubMed ID: 24901467
    [Abstract] [Full Text] [Related]

  • 25. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation.
    Ruggenenti P, Codreanu I, Cravedi P, Perna A, Gotti E, Remuzzi G.
    Clin J Am Soc Nephrol; 2006 May 05; 1(3):546-54. PubMed ID: 17699258
    [Abstract] [Full Text] [Related]

  • 26. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
    Pilch NA, Taber DJ, Moussa O, Thomas B, Denmark S, Meadows HB, McGillicuddy JW, Srinivas TR, Baliga PK, Chavin KD.
    Ann Surg; 2014 May 05; 259(5):888-93. PubMed ID: 24513787
    [Abstract] [Full Text] [Related]

  • 27. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.
    Thistlethwaite JR, Nashan B, Hall M, Chodoff L, Lin TH.
    Transplantation; 2000 Sep 15; 70(5):784-90. PubMed ID: 11003358
    [Abstract] [Full Text] [Related]

  • 28. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL, Wang D, Wu WZ, Lin WH, Xu TZ, Cai JQ, Tan JM.
    Transpl Immunol; 2008 Jan 15; 18(3):281-5. PubMed ID: 18047938
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
    Mattei MF, Redonnet M, Gandjbakhch I, Bandini AM, Billes A, Epailly E, Guillemain R, Lelong B, Pol A, Treilhaud M, Vermes E, Dorent R, Lemay D, Blanc AS, Boissonnat P.
    J Heart Lung Transplant; 2007 Jul 15; 26(7):693-9. PubMed ID: 17613399
    [Abstract] [Full Text] [Related]

  • 31. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
    Flaman F, Zieroth S, Rao V, Ross H, Delgado DH.
    J Heart Lung Transplant; 2006 Nov 15; 25(11):1358-62. PubMed ID: 17097501
    [Abstract] [Full Text] [Related]

  • 32. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
    Ponticelli C, Yussim A, Cambi V, Legendre C, Rizzo G, Salvadori M, Kahn D, Kashi H, Salmela K, Fricke L, Heemann U, Garcia-Martinez J, Lechler R, Prestele H, Girault D, Simulect Phase IV Study Group.
    Transplantation; 2001 Oct 15; 72(7):1261-7. PubMed ID: 11602853
    [Abstract] [Full Text] [Related]

  • 33. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.
    Wang W, Yin H, Li XB, Hu XP, Yang XY, Liu H, Ren L, Wang Y, Zhang XD.
    Chin Med J (Engl); 2012 Mar 15; 125(6):1135-40. PubMed ID: 22613543
    [Abstract] [Full Text] [Related]

  • 34. Basiliximab: efficacy and safety evaluation in kidney transplantation.
    Ponticelli C.
    Expert Opin Drug Saf; 2014 Mar 15; 13(3):373-81. PubMed ID: 24266670
    [Abstract] [Full Text] [Related]

  • 35. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.
    Lawen JG, Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L, Wilkinson AH, Mulloy LL, Bourbigot BJ, Prestele H, Korn A, Girault D, Simulect International Study Group.
    Transplantation; 2003 Jan 15; 75(1):37-43. PubMed ID: 12544868
    [Abstract] [Full Text] [Related]

  • 36. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.
    Gentile G, Somma C, Gennarini A, Mastroluca D, Rota G, Lacanna F, Locatelli B, Remuzzi G, Ruggenenti P.
    Am J Nephrol; 2015 Jan 15; 41(1):16-27. PubMed ID: 25612603
    [Abstract] [Full Text] [Related]

  • 37. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.
    Yao G, Albon E, Adi Y, Milford D, Bayliss S, Ready A, Raftery J, Taylor RS.
    Health Technol Assess; 2006 Dec 15; 10(49):iii-iv, ix-xi, 1-157. PubMed ID: 17134597
    [Abstract] [Full Text] [Related]

  • 38. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids.
    Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D.
    Transplantation; 2004 Aug 27; 78(4):584-90. PubMed ID: 15446319
    [Abstract] [Full Text] [Related]

  • 39. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST, Roberts KL, Malek SK, Tullius SG, Vadivel N, De Serres S, Grafals M, Elsanjak A, Filkins BA, Chandraker A, Gabardi S.
    Pharmacotherapy; 2011 Jun 27; 31(6):566-73. PubMed ID: 21923440
    [Abstract] [Full Text] [Related]

  • 40. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial.
    Carrier M, Leblanc MH, Perrault LP, White M, Doyle D, Beaudoin D, Guertin MC.
    J Heart Lung Transplant; 2007 Mar 27; 26(3):258-63. PubMed ID: 17346628
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 71.